top of page

Shulman M, Meyers-Ohki S, Novo P, Provost S, Ohrtman K, Van Veldhuisen P, Oden N, Otterstatter M, Bailey GL, Liu D, Rotrosen J, Weiss RD, Nunes EV. Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD). Contemporary Clinical Trials, Volume 150, 2025, 107816, ISSN 1551-7144. https://doi.org/10.1016/j.cct.2025.107816.

Bailey AJ, Votaw VR, Weiss RD, McHugh RK. Capturing the Full-Range of Buprenorphine Treatment Response. JAMA Psychiatry, 2024 Dec 4. doi: 10.1001/jamapsychiatry.2024.3836. Online ahead of print.PMID: 39630467

Weinstein ZM, Yu O, Wartko PD, Samet JH, Bobb JF, Braciszewski JM, Arnsten JH, Murphy MT, Horigian VE, Stotts AL, Beers D, Bradley K. Does implementation of office based addiction treatment by a nurse care manager increase the duration of OUD treatment in primary care? A secondary analysis of the PROUD randomized control trial. Drug and Alcohol Dependence, Volume 265, 2024, 112497. ISSN 0376-8716, https://doi.org/10.1016/j.drugalcdep.2024.112497.

Lu T, Ryan D, Cadet T, Chawarski MC, Coupet E Jr, Edelman EJ, Hawk KF, Huntley K, Jalali A, O'Connor PG, Owens PH, Martel SH, Fiellin DA, D'Onofrio G, Murphy SM. Cost-Effectiveness of Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine for Opioid Use Disorder. Ann Emerg Med. 2024 Nov 20:S0196-0644(24)01116-8. doi: 10.1016/j.annemergmed.2024.10.001. Online ahead of print. PMID: 39570250

Balter DR, Puglisi LB, Dziura J, Fiellin DA, Howell BA. Buprenorphine-naloxone vs. extended-releasenaltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondaryanalysis of the X:BOT randomized controlled trial. J Subst Use Addict Treat. 2024 Sep;164:209438. doi:10.1016/j.josat.2024.209438. Epub 2024 Jun 8. PMID: 38857827

Justen M, Edelman EJ, Chawarski M, Coupet E, Cowan E, Lyonsf M, Owens P, Martel S, Richardson L, Rothman R, Whiteside L, O'Connor P, Zahni E, D'Onofrio G, Fiellin D, Hawk K. Perspectives on and experiences of emergency department–initiated buprenorphine among clinical pharmacists: A multi-site qualitative study. Journal of Substance Use & Addiction Treatment, Volume 155, 209058

Recent Publications

Protocol publications (select each protocol)

EMS Initiated Buprenorphine for Opioid Use Disorder

Adolescent outcomes of Post-operative opioid Exposure (APEX) (NIH HEAL Initiative)

Standard versus High Dose ED-Initiated Buprenorphine Induction (NIH HEAL Initiative)

Office-Based Methadone versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment – A Randomized Pragmatic Hybrid Effectiveness/Implementation Trial

Longitudinal Follow-up of Individuals with Opioid Use Disorder

Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (NIH HEAL Initiative)

Emergency Department-INitiated bupreNOrphine and VAlidaTIOn Network Trial (ED-INNOVATION)

Sub Study: Emergency Department-INitiated bupreNOrphine and VAlidaTIOn Network Trial (ED-INNOVATION)

Racial/Ethnic Disparities in Addiction Treatment Access for Opioid Use Disorder from the Emergency Department

Emergency Medicine Opioid Data Infrastructure: Key Venue to Address Opioid Morbidity and Mortality (Project CODE PRO--Capturing Opioid Use Disorder Electronically and Patient Reported Outcomes)

Emergency Department Connection to Care with Buprenorphine for Opioid Use Disorder (ED-CONNECT)

Sub Study: Emergency Department Connection to Care with Buprenorphine for Opioid Use Disorder (ED-CONNECT)

Primary Care Opioid Use Disorder (PROUD) Treatment Trial

Opioid Use Disorder in the Emergency Department (Project ED Health)

Retrospective Evaluation of High Dose Buprenorphine Induction in the Emergency Department for Opioid Use Disorder

The Impact of COVID-19 on Individuals with Opioid Use Disorder Who Received Emergency Department Care: A Survey Study of Project ED Health Participants and Medical Leadership at Four EDs

Validating 3 Substance Use Screening Tools for Adolescents

Prescription Opioid Addiction Treatment Study (POATS)

MET (Motivational Enhancement Treatment) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse

MI (Motivational Interviewing) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse

Motivational Enhancement Treatment to Improve Treatment Engagement and Outcome for Spanish-Speaking Individuals Seeking Treatment for Substance Abuse

bottom of page